Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



{{PANUMCODE}}

Krazati

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, Please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat Phy	ient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}} ient's ID: {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} ysician's Name: {{PHYFIRST}} {{PHYLAST}}
Phy Rec	cialty:
l.	What is the patient's diagnosis? ☐ Non-small cell lung cancer (NSCLC) ☐ Pancreatic Adenocarcinoma ☐ Other
2.	What is the ICD-10 code?
3.	Is the patient currently receiving treatment with the requested medication? \square Yes \square No If No, skip to #5
1.	Is there evidence of unacceptable toxicity or disease progression while on the current regimen? ☐ Yes ☐ No No further questions.
5.	What is the clinical setting in which the requested medication will be used? ☐ Advanced disease ☐ Metastatic disease ☐ Locally advanced disease ☐ Other
5.	Is the tumor or plasma specimen positive for the KRAS G12C mutation? <i>ACTION REQUIRED: If Yes, attach supporting chart notes or test results confirming KRAS G12C mutation status.</i> \square Yes \square No \square Unknown
Cor	mplete the following section based on the patient's diagnosis, if applicable.
	tion A: Non-Small Cell Lung Cancer (NSCLC) Has the patient received at least one prior systemic therapy? Yes No
	tion B: Pancreatic Adenocarcinoma What is the patient's Eastern Cooperative Oncology Group (ECOG) performance status? □ 0-2 □ 3 or greater
).	Will the requested medication be used as a single agent? ☐ Yes ☐ No
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by CVS Caremark or the benefit plan sponsor.
\ _	
>re	escriber or Authorized Signature Date (mm/dd/yy)

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Krazati SGM - 7/2023.